SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...

What Is Forteo and How Does It Work? Teriparatide (Forteo) is an osteoporosis medicine approved by the FDA that rebuilds bone. (Bonsity is another FDA-approved version of teriparatide.) Teriparatide ...

In a head-to-head comparison of the two drugs, Forteo increased lumbar spine density measurements by 7.2 percent compared to 3.4 percent for Fosamax, and it boosted hip density measurements by 3.8 ...

Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today. Lilly can now promote Forteo as a therapy for men and women ...

Forteo promotes rapid bone formation in the femoral neck, with pronounced effects in cancellous and endocortical bone envelopes, according to recent findings. Felicia Cosman, MD, an endocrinologist at ...

Forteo (teriparatide) is a brand-name medication that doctors may prescribe to treat osteoporosis. The drug uses proteins to enhance bone strength and promote the development of new bone tissue. You ...

Ambio announced that a generic version of Forteo (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the Food and Drug Administration. Forteo ...

The FDA has approved its NDA for PF708 under the 505(b)(2) regulatory pathway, with Amgen, Inc. AMGN's Forteo as the reference drug. PF708 has been indicated to treat osteoporosis in certain patients ...

Amgen's ($AMGN) investigational bone-growing drug met its main goal in a late-stage trial, clearing its first Phase III hurdle by besting an Eli Lilly ($LLY ...